Literature DB >> 17428588

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

Joachim Hombach1, M Jane Cardosa, Arunee Sabchareon, David W Vaughn, Alan D T Barrett.   

Abstract

Several dengue vaccine candidates have been evaluated in early clinical phase, and some are scheduled for efficacy testing in population-based studies. Given the advancements in dengue vaccine development, there is an increased interest in identifying immunological correlates of protection for these vaccines in order to facilitate their evaluation, further refinement, production and registration. To this end, the WHO Initiative for Vaccine Research (IVR) convened a consultation on primary and secondary immunological correlates of protection induced by dengue vaccines. The meeting was held on the 17th and 18th of November, 2005 at WHO headquarters in Geneva. The consultation was a first dedicated review of the available data in support of establishing correlates. It is concluded that it is not yet possible to define one specific set of correlates, the consultation concluded in recommendations that should help to gather the missing evidence in conjunction with future vaccine trials.

Mesh:

Substances:

Year:  2007        PMID: 17428588     DOI: 10.1016/j.vaccine.2007.02.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

Review 2.  Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas.

Authors:  G William Letson; Pratap Singhasivanon; Eduardo Fernandez; Nihal Abeysinghe; Juan Jose Amador; Harold S Margolis; Robert Edelman
Journal:  Hum Vaccin       Date:  2010-10-01

Review 3.  Dengue: a continuing global threat.

Authors:  Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling
Journal:  Nat Rev Microbiol       Date:  2010-12       Impact factor: 60.633

4.  Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes.

Authors:  Lidice Bernardo; Osmel Fleitas; Alequis Pavón; Lisset Hermida; Gerardo Guillén; Maria G Guzman
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

5.  Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers.

Authors:  Willem G van Panhuis; Robert V Gibbons; Timothy P Endy; Alan L Rothman; Anon Srikiatkhachorn; Ananda Nisalak; Donald S Burke; Derek A T Cummings
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

6.  Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.

Authors:  Naoko Uno; Ted M Ross
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

7.  Dengue in Vietnamese infants--results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity.

Authors:  Tran Nguyen Bich Chau; Nguyen Than Ha Quyen; Tran Thi Thuy; Nguyen Minh Tuan; Dang Minh Hoang; Nguyen Thi Phuong Dung; Le Bich Lien; Nguyen Thien Quy; Nguyen Trong Hieu; Lu Thi Minh Hieu; Tran Tinh Hien; Nguyen Thanh Hung; Jeremy Farrar; Cameron P Simmons
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

8.  Role of CD61+ cells in thrombocytopenia of dengue patients.

Authors:  Sansanee Noisakran; Nattawat Onlamoon; Kovit Pattanapanyasat; Hui-Mien Hsiao; Pucharee Songprakhon; Nasikarn Angkasekwinai; Kulkanya Chokephaibulkit; Francois Villinger; Aftab A Ansari; Guey Chuen Perng
Journal:  Int J Hematol       Date:  2012-09-18       Impact factor: 2.490

9.  An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.

Authors:  Laura J White; Melissa M Parsons; Alan C Whitmore; Brandon M Williams; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

10.  Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.

Authors:  Wayne D Crill; Holly R Hughes; Mark J Delorey; Gwong-Jen J Chang
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.